You just read:

Helsinn Group and Eisai Inc. Announce Start of Phase III Clinical Program of Oral Fixed-DOSE Combination of Netupitant/Palonosetron (300 mg/0.50 mg) for Prevention of CINV

News provided by

Helsinn Healthcare SA

23 Sep, 2011, 11:00 BST